| Molecular mechanisms of polymyxin resistance: knowns and unknowns | 2016/12/01 | English | 280 |
| Chloroquine for the 2019 novel coronavirus SARS-CoV-2 | 2020/03/01 | English | 274 |
| Antimicrobial resistance in aquaculture: Current knowledge and alternatives to tackle the problem | 2018/08/01 | English | 272 |
| Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century | 2007/10/01 | English | 270 |
| Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? | 2007/06/01 | English | 265 |
| Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options | 2012/02/01 | English | 256 |
| Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept | 2010/10/01 | English | 255 |
| What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline | 2011/05/01 | English | 253 |
| Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter | 2004/03/01 | English | 251 |
| Antibacterial activities of inorganic agents on six bacteria associated with oral infections by two susceptibility tests | 2006/06/01 | English | 250 |
| Resistance to polymyxins in Gram-negative organisms | 2017/05/01 | English | 250 |
| Candidaemia in Europe: epidemiology and resistance | 2006/05/01 | English | 248 |
| The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections | 2009/11/01 | English | 244 |
| Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status | 2020/04/01 | English | 237 |
| Oxazolidinones: activity, mode of action, and mechanism of resistance | 2004/02/01 | English | 236 |
| Increased antimicrobial resistance during the COVID-19 pandemic | 2021/04/01 | English | 234 |
| Antibacterial and antifungal properties of resveratrol | 2019/06/01 | English | 234 |
| Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance | 2010/03/01 | English | 229 |
| Bacteraemia in febrile neutropenic cancer patients | 2007/11/01 | English | 222 |
| Epidemiology of prostatitis | 2008/02/01 | English | 219 |
| Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients | 2010/02/01 | English | 219 |
| Antimicrobial and healing activity of kefir and kefiran extract | 2005/05/01 | English | 219 |
| Arguments in favour of remdesivir for treating SARS-CoV-2 infections | 2020/04/01 | English | 216 |
| Bacteriophages: an appraisal of their role in the treatment of bacterial infections | 2007/08/01 | English | 213 |
| Ivermectin: 25 years and still going strong | 2008/02/01 | English | 210 |
| Extra-respiratory manifestations of COVID-19 | 2020/08/01 | English | 210 |
| Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections | 2014/06/01 | English | 209 |
| Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study | 2014/12/01 | English | 207 |
| Antimicrobial resistance in developing countries and responsible risk factors | 2004/08/01 | English | 205 |
| Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities | 2014/01/01 | English | 202 |